The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy
Weight gain is not simply caused by overeating hormones, insulin resistance, metabolism, genetics, stress, and appetite regulation all play important roles
Common side effects reported in trials include: Nausea and vomiting (most common during titration) Diarrhea or constipation Decreased appetite (generally desired) Mild injection site reactions Fatigue during early treatment phases Serious side effects are rare but may include pancreatitis or gallbladder issues
It works like other GLP-1 treatments by helping the body release insulin when blood sugar is high, lowering glucagon, slowing how quickly food leaves the stomach, and reducing appetite